share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q:2024財年一季報
美股SEC公告 ·  05/08 19:18

牛牛AI助理已提取核心訊息

Cingulate Inc., a biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $2.972 million, a decrease from the $4.004 million loss in the same period the previous year. This reduction in net loss was attributed to a decrease in both research and development expenses, which dropped by 15.1% to $1.807 million, and general and administrative expenses, which fell by 35.1% to $1.117 million. The company's financial position was bolstered by the issuance of common stock under an ATM Agreement and a public offering in February 2024, which provided net proceeds of $3.115 million and $7.5 million, respectively. Cingulate Inc. is focused on developing products for the treatment of ADHD and anxiety, with its lead product candidate, CTx-1301, having completed...Show More
Cingulate Inc., a biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $2.972 million, a decrease from the $4.004 million loss in the same period the previous year. This reduction in net loss was attributed to a decrease in both research and development expenses, which dropped by 15.1% to $1.807 million, and general and administrative expenses, which fell by 35.1% to $1.117 million. The company's financial position was bolstered by the issuance of common stock under an ATM Agreement and a public offering in February 2024, which provided net proceeds of $3.115 million and $7.5 million, respectively. Cingulate Inc. is focused on developing products for the treatment of ADHD and anxiety, with its lead product candidate, CTx-1301, having completed enrollment in two Phase 3 clinical trials. The company plans to submit a New Drug Application for CTx-1301 in the first half of 2025. Additionally, Cingulate Inc. is developing CTx-1302 and CTx-2103, with plans to initiate clinical plans for CTx-1302 as soon as 2025, pending additional capital resources. The company's future plans include seeking regulatory approval for its product candidates, continuing research and development, and potentially commercializing its products if approval is obtained.
生物製藥公司Cingulate Inc.報告了截至2024年3月31日的財務業績。該公司淨虧損297.2萬美元,較去年同期的400.4萬美元虧損有所減少。減少的淨虧損歸因於其研發支出和一般行政費用的下降。研發費用下降了15.1%,至180.7萬美元,一般行政費用下降了35.1%,至111.7萬美元。該公司的財務狀況得到了一項ATM協議下的普通股股份發行和2024年2月的公開招股,分別提供了淨收益311.5萬美元和750萬美元。Cingulate Inc.專注於開發用於治療注意力缺陷/多動障礙和焦慮症的產品,並且旗艦產品候選CTx-1301已經完成了兩項III期臨床試驗的入組。該公司計劃在202...展開全部
生物製藥公司Cingulate Inc.報告了截至2024年3月31日的財務業績。該公司淨虧損297.2萬美元,較去年同期的400.4萬美元虧損有所減少。減少的淨虧損歸因於其研發支出和一般行政費用的下降。研發費用下降了15.1%,至180.7萬美元,一般行政費用下降了35.1%,至111.7萬美元。該公司的財務狀況得到了一項ATM協議下的普通股股份發行和2024年2月的公開招股,分別提供了淨收益311.5萬美元和750萬美元。Cingulate Inc.專注於開發用於治療注意力缺陷/多動障礙和焦慮症的產品,並且旗艦產品候選CTx-1301已經完成了兩項III期臨床試驗的入組。該公司計劃在2025年上半年提交CTx-1301的新藥申請。此外,Cingulate Inc.正在開發CTx-1302和CTx-2103,並計劃在2025年開始CTx-1302的臨床計劃,前提是獲得額外的資本資源。該公司未來的計劃包括尋求產品候選的監管批准,繼續開展研究和開發,並在獲得批准後可能將其產品商業化。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。